EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR ‐mutated NSCLC : translational research of phase III IMPACT study

Satoshi Ikeda iD, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada und 20 weitere

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Satoshi Ikeda und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca KK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor ( EGFR )‐mutated non‐small cell lung cancer (NSCLC). Although the primary endpoint of disease‐free survival (DFS) was not met, we searched for molecular predictors of adjuvant gefitinib efficacy. Of 234 patients enrolled in the IMPACT study, 202 patients were analyzed for 409 cancer‐related gene mutations and tumor mutation burden using resected lung cancer specimens. Frequent somatic mutations included tumor protein p53 ( TP53 ; 58.4%), CUB and Sushi multiple domains 3 ( CSMD3 ; 11.8%), and NOTCH1 (9.9%). Multivariate analysis showed that NOTCH1 co‐mutation was a significant poor prognostic factor for overall survival (OS) in the gefitinib group and cAMP response element binding protein ( CREBBP ) co‐mutation for DFS and OS in the cis/vin group. In patients with NOTCH1 co‐mutations, gefitinib group had a shorter OS than cis/vin group (Hazard ratio 5.49, 95% CI 1.07–28.00), with a significant interaction ( P for interaction = 0.039). In patients with CREBBP co‐mutations, the gefitinib group had a longer DFS than the cis/vin group, with a significant interaction ( P for interaction = 0.058). In completely resected EGFR ‐mutated NSCLC, NOTCH1 and CREBBP mutations might predict poor outcome in patients treated with gefitinib and cis/vin, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansGefitinibCyclic AMP Response Element-Binding ProteinTranslational Research, BiomedicalErbB ReceptorsCisplatinVinorelbineMutationProtein Kinase InhibitorsReceptor, Notch1CREB-Binding Protein

Stichwörter der Autor:innen

adjuvant therapyearly-stageepidermal growth factor receptornon-small cell lung cancertyrosine kinase inhibitor

Substanzen

GefitinibCyclic AMP Response Element-Binding ProteinErbB ReceptorsCisplatinVinorelbineProtein Kinase InhibitorsNOTCH1 protein, humanReceptor, Notch1CREBBP protein, humanCREB-Binding Protein

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
  • Division of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Department of Data Science, National Cancer Center Hospital East, Kashiwa, Japan.
  • Internal Medicine III, Wakayama Medical University, Japan.
  • Department of Respiratory Medicine, Hiroshima Citizens Hospital, Japan.

ORCID-Profile: Satoshi Ikeda, Kazuto Nishio

Förderung

  • AstraZeneca KK

Zitieren

APA

Ikeda, S., Tsuboi, M., Sakai, K., Misumi, T., Akamatsu, H., Shoda, H., Sakakura, N., Nakamura, A., Ohde, Y., Hayashi, H., Okishio, K., Okada, M., Yoshino, I., Okami, J., Takahashi, K., Ikeda, N., Tanahashi, M., Tambo, Y., Saito, H., …, & Nishio, K. (2024). NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR ‐mutated NSCLC : translational research of phase III IMPACT study. Molecular Oncology. https://doi.org/10.1002/1878-0261.13542

Vancouver

Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, et al. NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR ‐mutated NSCLC : translational research of phase III IMPACT study. Molecular Oncology. 2024. doi:10.1002/1878-0261.13542

BibTeX
@article{Ikeda2024,
  author = {Ikeda, Satoshi and Tsuboi, Masahiro and Sakai, Kazuko and Misumi, Toshihiro and Akamatsu, Hiroaki and Shoda, Hiroyasu and Sakakura, Noriaki and Nakamura, Atsushi and Ohde, Yasuhisa and Hayashi, Hidetoshi and Okishio, Kyoichi and Okada, Morihito and Yoshino, Ichiro and Okami, Jiro and Takahashi, Kazuhisa and Ikeda, Norihiko and Tanahashi, Masayuki and Tambo, Yuichi and Saito, Haruhiro and Toyooka, Shinichi and Inokawa, Hidetoshi and Chen-Yoshikawa, Toyofumi and Yokoyama, Toshihide and Okamoto, Tatsuro and Yanagitani, Noriko and Oki, Masahide and Takahama, Makoto and Sawa, Kenji and Tada, Hirohito and Nakagawa, Kazuhiko and Mitsudomi, Tetsuya and Nishio, Kazuto},
  title = {NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR ‐mutated NSCLC : translational research of phase III IMPACT study},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13542}
}
Kostenlos starten →